Products For The Global Market

XTANDI (Prostate cancer treatment)

XTANDI is a treatment that decreases cell growth and induces apoptosis by inhibiting multiple steps in the androgen receptor signaling pathway, an important pathway in the growth of prostate cancer.  XTANDI was first launched in 2012 with an indication for the treatment patients with metastatic castration-resistant prostate cancer (CRPC) whose disease has progressed on or after chemotherapy. Subsequently, it has also been approved for metastatic chemo-naïve CRPC patients. XTANDI is sold in approximately 70 countries/areas.

Eligard (Prostate cancer treatment)

Eligard is a luteinizing hormone-releasing hormone (LHRH) agonist for the treatment of prostate cancer that is marketed by Astellas in approximately 50 countries throughout the EMEA and Asia & Oceania regions.

Betanis / Myrbetriq / BETMIGA (OAB treatment)

Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.  Mirabegron is the only OAB treatment option in its class that targets the β3 pathway.  Mirabegron is sold in approximately 50 countries worldwide under the brand name of Betanis in Japan, Myrbetriq in the U.S. and Canada, Myrbetric in Latin America, and BETMIGA in EU, MENASA, Russia/CIS, and Asia & Oceania.

Vesicare (OAB treatment)

Solifenacin is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.  Solifenacin binds to certain natural body proteins (receptors) which help the bladder muscle to contract. This can help control the symptoms of frequent urges and leaks.  Solifenacin is now marketed in approximately 80 countries worldwide.

Harnal / Omnic (Treatment for functional symptoms associated with benign prostatic hyperplasia (BPH))

Tamsulosin is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).  Tamsulosin is an α1 blocking agent with great selectivity for prostatic and urethral smooth muscle.  It is marketed in approximately 100 countries worldwide.


VESOMNI is a modified release tablet of combination 6 mg solifenacin and 0.4 mg tamsulosin.  VESOMNI is indicated for the treatment of moderate to severe storage symptoms (urgency, increased micturition frequency) and voiding symptoms associated with benign prostatic hyperplasia (BPH) in men who are not adequately responding to treatment with monotherapy.  VESOMNI is marketing in approximately 20 countries worldwide.

Prograf and Advagraf / Graceptor / ASTAGRAF XL / Prograf XL (Immunosuppressant)

This drug is an immunosuppressant used to suppress organ transplant rejection. It is sold in approximately 100 countries and regions and has made a significant global contribution in the field of transplantation.

Funguard / MYCAMINE (Candin-type antifungal agent)

This drug is a candin-type antifungal agent used for the treatment of fungal infections.
It operates by inhibiting synthesis of the fungus cell wall. It is marketed in about 60 countries around the world.


Leading Products in Japan

Micardis / Micombi / Micamlo (a treatment for hypertension)
Celecox (Anti-inflammatory agent)
Symbicort (Treatment for adult bronchial asthma and chronic obstructive pulmonary disease)
Bonoteo (Treatment for osteoporosis)
Suglat (Type 2 diabetes treatment)
Repatha (Hypercholesterolemia treatment)Close

Leading Products in North America

Lexiscan (a pharmacologic stress agent)
Tarceva (a treatment for non-small cell lung cancer)
CRESEMBA (Azole antifungal)Close

Leading Products in Europe

Dificlir (a novel treatment for CDI)Close